Immupharma

Health medical diagnostics pharma platform

ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. Lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Lupuzor ™ has 'Gold Standard' approval from the US FDA for its Phase III trial with a Special Protocol Assessment and "Fast Track" designation. Lupuzor ™ has now commenced its Phase III pivotal trial.

Revenue(FY, 2017)

£150.5 K

Type

Public

London, GB

Size (employees)

10 (est)

Website

immupharma.org

Immupharma is headquartered in London, GB

Report incorrect company information

Immupharma Office Locations

Open Map View

Immupharma has offices in London, Mulhouse and Sarnen

London, GB (HQ)

50 Broadway

Mulhouse, FR

5 Rue du Rhône

Sarnen, CH

10 Poststrasse

Show all (3)

Report incorrect company information

Immupharma Financials and Metrics

Immupharma Revenue

Immupharma's revenue was reported to be £150.46 k in FY, 2017

Summary

GBP
Revenue (FY, 2017)	150.5 k
Net income (FY, 2017)	(6.2 m)
EBITDA (FY, 2017)	(7.1 m)
EBIT (FY, 2017)	(7.2 m)
Cash (31-Dec-2017)	2.7 m

Income Statement

GBP	FY, 2006	FY, 2007	FY, 2008	FY, 2009	FY, 2010	FY, 2011	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	25.4 k	63.2 k	57.1 k	22.1 m	32.5 k	16.8 k			184.8 k	76.4 k	164.8 k	150.5 k
Revenue growth, %										(59%)
Operating expense total	(1.5 m)	3.6 m	4.6 m	11.8 m	4.2 m	(3.8 m)			3.6 m	4.6 m	6.8 m	7.4 m
EBITDA	(2 m)	(3.5 m)	(4.5 m)	10.3 m	(4.1 m)	3.9 m	(4.1 m)	(4.2 m)	(3.3 m)	(4.4 m)	(6.5 m)	(7.1 m)

show all

Balance Sheet

GBP	FY, 2001	FY, 2002	FY, 2003	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2008	FY, 2009	FY, 2010	FY, 2011	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	1	1	1	978.2 k	1 m	2.7 m	2.9 m	12.5 m	22.5 m	15.6 m	12.2 m	8.9 m	5.4 m	5.4 m	833.4 k	1.9 m	2.7 m
Accounts Receivable									3.2 k	22.2 k	2.8 k	13.2 k
Current Assets	1	1	1	979.9 k	1 m	2.9 m	3.3 m	12.6 m	23.9 m	16.8 m	13.5 m	9.8 m	6.5 m	6.1 m	2.4 m	6 m	4.4 m
PP&E						12 k	12.8 k	13.3 k	9.3 k	76.8 k	125.4 k	114.8 k	97.1 k	366.4 k	280.1 k	231.9 k	161.4 k

show all

Cash Flow

GBP	FY, 2004	FY, 2005	FY, 2006	FY, 2007	FY, 2008	FY, 2009	FY, 2010	FY, 2011	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	1.4 k	15.1 k	(2.5 m)	(3.1 m)	4.7 m	8.1 m	(2 m)	(3.4 m)	(3.8 m)	(3.7 m)	(2.9 m)	(3.9 m)	(5.3 m)	(6.2 m)
Cash From Operating Activities	15.8 k	18.3 k	879.6 k	3.8 m	(3.6 m)	12 m	(6.8 m)	(3.4 m)	(3.3 m)	(3.9 m)	(2.5 m)	(4.1 m)	(6.5 m)	(4.4 m)
Cash From Financing Activities	977 k		3 m	(77.6 k)	12 m	(143.5 k)	555.2 k	165.3 k	356.9 k	191.5 k	3 m	(310.1 k)	7.4 m	5.4 m
Net Change in Cash	978.2 k	27.1 k	2.7 m	3.7 m	8.5 m	11.9 m	(6.4 m)	(3.2 m)	(2.8 m)	(3.7 m)	199 k	(4.5 m)	896.3 k	945.9 k